Skip to main content
. 2021 Mar 19;4(1):1–16. doi: 10.20517/cdr.2020.61

Figure 1.

Figure 1

Overview of EV-mediated mechanisms of drug resistance. EVs derived from (A) resistant tumor cells and (B) tumor supporting cells transfer genomic and proteomic cargo to glioma treatment sensitive cells, which enhances their acquisition of a resistant phenotype; (C) EVs also function as decoys for antibody-based therapies, leading to the sequestration of anticancer antibodies; (D) EVs package and export drugs out of the cells, reducing its intracellular concentration